Solenis Acquires Nopco Colombiana

(c) Lichtmeister/Shutterstock
(c) Lichtmeister/Shutterstock

Following an agreement signed in May, US specialty chemical company Solenis has completed the acquisition of Nopco Colombiana. Financial details were not disclosed.  Headquartered in Medellin, Colombia, Nopco Colombiana was originally Solenis’ pulp and paper specialty chemical distributor in Central and South America.

The South American company is a leading producer and supplier of specialized chemical solutions for water-intensive industries such as pulp and paper, oil and gas, food and beverage, among others. Its products include wet strength resins, antiscalants, dispersants and defoamers, which are supplied to markets in Colombia, Ecuador and Peru.

“This acquisition represents Solenis’ commitment to direct channel investments in strategic growth markets. The addition of Nopco Colombiana allows the US firm to expand its capabilities to serve the growing process and water-treatment markets in Central and South America,” said John Panichella, president and CEO of Solenis, said.

The deal follows Solenis’ acquisition of Nopco Holding, a Norwegian producer of specialty chemicals for the pulp and paper industry, in September 2016.

Solenis was formerly known as Ashland Water Technologies. The name change coincided with the acquisition of Ashland Water Technologies in July 2014 by a fund managed by private equity company Clayton, Dubilier & Rice for around $1.8 billion. Solenis said it is focused on growing the business in the areas of process and water technologies.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read